Centre Médical de l'Institut Pasteur
Paris, 75015, France
Location status: Recruiting
NCT Number: NCT06718127
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.
The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Paris, 75015, France
Location status: Recruiting
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.
For example, research has shown that the live attenuated BCG vaccine induce non-specific trained immunity, enabling innate immune cells to remember their first encounter and improve their immune status during a second confrontation with similar or different agents.
Other currently available live vaccines, such as BCG , could also "train" innate immune cells.
The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
blood samples collected at D0 ,W1, W5, M3 and M6
Time frame: 6 months
Cytokine production assays (e.g. TNFa, IL6, IL1b)
Time frame: 6 months
ELISA-based quantification of Anti-Vi antibody level >30 U/mL at week 5, and/or fold increase ≥2 compared with pre-vaccination IgG titer.
Contact information is provided by the study sponsor or research team.
Institut Pasteur
Industry
Acronym: IVORY2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02200276
Immunization, Infections
Baltimore, Maryland, United States
View Trial DetailsNCT05672927
Communicable Diseases, DNA Virus Infections
Galveston, Texas, United States
View Trial DetailsNCT05213000
Immunization
Ames, Iowa, United States
View Trial DetailsNCT04936776
Hematologic Diseases, Hemic and Lymphatic Diseases
New York, United States
View Trial Details